Synthesis method of semeglutide
Through the methods of shard synthesis and liquid phase synthesis, the problem of missing peptides and impurities in semegglutide synthesis is solved, the purity and yield are improved, and it is suitable for industrial production, avoiding the use of heavy metals and genotoxic substances.
Patent Information
- Application Number
- CN202411090858.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-15
AI Technical Summary
In the existing method of smegglutide synthesis, there are many missing peptides and impurities produced by amino acid condensation, which are difficult to purification, low overall yield, and there are problems with the use of heavy metals and genotoxic substances.
Using the fragmentation synthesis method, fragments of amino acids at positions 21-31, 9-15 and 1-8 were synthesized respectively in solid phase, and amino acids at the side chain with liquid phase were synthesized from the C-terminus according to the peptide sequence. Coupling to the N-terminus was sequentially coupled to the cleavage and precipitation steps to obtain the crude semegglutide product.
It improves the purity and yield of semegglutide, reduces the difficulty of preparation and material cost, avoids the use of heavy metals and genotoxic substances, and is suitable for industrial production.
Smart Images

Figure CN118955683A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of polypeptide synthesis, and in particular to a method for synthesizing semaglutide. Background Art
[0002] Sermaglutide, English name Sermaglutide, its peptide sequence structure is: H-His 1 -Aib 2 -Glu 3 -Gly 4 -Thr 5 -Phe 6 -Thr 7 -Ser 8 -Asp 9 -Val 10 -Ser 11 -Ser 12 -Tyr 13 -Leu 14 -Glu 15 -Gly 16 -Gln 17 -Ala 18 -Ala 19 -Lys 20 (AEEA-AEEA-γ-Glu-Ste)-Glu 21 -Phe 22 -Ile 23 -Ala 24 -Trp 25 -Leu 26 -Val 27 -Arg 28 -Gly 29 -Arg 30 -Gly 31 -OH. The structural formula is as follows: Semaglutide is a new long-acting glucagon-like peptide-1 (GLP-1) analog that lowers blood sugar by stimulating insulin secretion and reducing glucagon secretion. The original research company is Novo Nordisk. On December 5, 2017, Semaglutide injection (trade name Ozempic) was approved by the FDA and launched on the market. It is used to control blood sugar in adult patients with type 2 diabetes who do not meet blood sugar targets on the basis of diet control and exercise and who receive metformin and / or sulfonylurea drugs.
[0003] At present, the synthesis methods of semaglutide, such as patents: CN106478806A and CN101133082A, use the Fmoc strategy to step-by-step coupling to synthesize semaglutide. This method of step-by-step coupling of amino acids has a long synthesis cycle, incomplete reaction, more accumulated impurities, difficult purification, and low overall yield. CN110372785A uses two fragments, Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA-OH and Fmoc-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val-OH, which reduces some impurities and improves purity and yield, but Lys20 uses Fmoc-Lys(Alloc)-OH, and Pd(PPh 3 ) 4 , heavy metal Pd is introduced, and subsequent Pd residue detection is required; the 20th Lys in CN112028986A is orthogonally protected by Dde-Lys(Fmoc)-OH, but genotoxic hydrazine hydrate is required to remove the Dde protecting group. Summary of the invention
[0004] The object of the present invention is to provide a method for synthesizing semaglutide, which can effectively avoid deletion peptides, differential peptides, etc. generated by amino acid condensation one by one, improve the purity of the crude product, reduce the difficulty of preparing and purifying the crude semaglutide product, improve the product yield, reduce the material cost, and is suitable for industrial production.
[0005] To achieve the above object, the technical solution adopted by the present invention is: A method for synthesizing semaglutide comprises the following steps: respectively solid-phase synthesizing a first fragment of amino acids at positions 21-31, a third fragment of amino acids at positions 9-15, and a fourth fragment of amino acids at positions 1-8; liquid-phase synthesizing a second fragment with amino acid at position 20 on the side chain; sequentially coupling the first fragment, the second fragment, the third fragment, and the fourth fragment from the C-terminus to the N-terminus according to the peptide sequence of semaglutide to obtain semaglutide resin, and then cleaving and precipitating to obtain a crude semaglutide product.
[0006] Preferably, the solid phase synthesis method of the first fragment is: using Wang Resin as a solid phase carrier, sequentially coupling Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH•H20, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, removing the N-terminal Fmoc protecting group to obtain H-Glu(OtBu)21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0007] Preferably, the solid phase synthesis method of the third fragment is: using 2-CTC Resin as a solid phase carrier, using Fmoc-Glu(OtBu)-OH to transform the resin, and then sequentially coupling Fmoc-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH to obtain a fully protected resin for the third fragment, and using a cleavage solution to perform fully protected cleavage to obtain the third fragment Fmoc-Asp(OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu) 12 -Tyr(tBu) 13 -Leu 14 -Glu(OtBu) 15 -OH.
[0008] Preferably, the solid phase synthesis method of the fourth fragment is: using 2-CTC Resin as a solid phase carrier, using Fmoc-Ser(tBu)-OH to transform the resin, and then sequentially coupling Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Boc-His(Trt)-Aib-OH to obtain a fully protected resin for the fourth fragment, and using a cleavage solution to perform fully protected cleavage to obtain the fourth fragment Boc-His(Trt) 1 -Aib 2 -Glu(OtBu) 3 -Gly 4 -Thr(tBu) 5 -Phe 6 -Thr(tBu) 7 -Ser(tBu) 8 -OH.
[0009] Preferably, the liquid phase synthesis method of the second fragment is: using tBu-Oct-OH as the starting material, condensing H-Glu-OtBu, H-AEEA-AEEA-OH, and Fmoc-Lys-OH•HCl in sequence from the N-terminus to the C-terminus to obtain Fmoc-Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-OH.
[0010] Preferably, the substitution degree of Wang Resin ranges from 0.2mmol / g to 1.0mmol / g, preferably 0.3 to 0.8mmol / g, more preferably 0.5 to 0.7mmol / g. The substitution value of 2-CTC Resin ranges from 0.4mmol / g to 1.5mmol / g, preferably 0.6 to 1.3mmol / g, more preferably 0.8 to 1.2mmol / g. The fully protective cleavage reagent is 10% to 30% TFE / DCM or 0.5% to 2% TFA / DCM solution, preferably 20% TFE / DCM solution.
[0011] Preferably, the volume ratio of the cleavage reagent used in the cleavage step of the semaglutide resin is TFA:TIS:EDT:H 2 O=85-95:2-5:0-2:2-5, the cracking time is 1.5h-3.0h, preferably 2.0-2.5h; the cracking temperature is 20℃-30℃, preferably 23-27℃.
[0012] Preferably, the precipitation reagent used in the precipitation step of the semaglutide resin is ethyl ether, isopropyl ether or methyl tert-butyl ether.
[0013] Preferably, the coupling reagents used for coupling between amino acids in a fragment and between adjacent fragments are A+B, A+B+D or C+D, wherein A is HOAt, HOBt, 6-Cl-HOBt, HONB, ethyl 2-oximecyanoacetate, B is DIC, DCC, EDC•HCl, C is HATU, HBTU, TBTU, TSTU, PyBOP, PyAOP, and D is DIEA, DMAP, NMM. Preferably, the combination of HOBt / DIC / DMAP, the combination of HBTU / DIEA, and the combination of HOBt / DIC are used.
[0014] Preferably, the deprotection solution for removing the Fmoc protecting group in the first fragment, the third fragment and the fourth fragment is a 10% to 20% piperidine / DMF mixed solution or a 3% to 10% DBU / DMF mixed solution.
[0015] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention has high purity, high yield and short cycle. The purity of the crude product reaches 85% and the total yield reaches 43%. It reduces the difficulty of preparing and purifying the crude semaglutide, improves the product yield, reduces the material cost, and is suitable for industrial production.
[0016] (2) The second fragment Fmoc-Lys(Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA)-OH was synthesized in liquid phase, which effectively reduced the material cost, avoided the introduction of genotoxic substances such as Pd heavy metal and hydrazine hydrate, and solved the problem of incomplete coupling of direct coupling of octadecane dioic acid.
[0017] (3) In the prior art, 10 -Ser 11 -Ser 12 The site is prone to form β-folding, resulting in steric hindrance, covering up the coupling site, causing coupling difficulties and the generation of missing peptides. The present invention uses a third fragment Fmoc-Asp(OtBu)-Val-Ser(tBu)-Ser(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-OH. This fragment is shorter and less likely to form a spatial structure, and does not contain hydrogen bond receptors, thereby avoiding the formation of β-folding and solving the problems of missing peptides and coupling difficulties.
[0018] (4) In the prior art, coupling to Ser 8 When the peptide sequence is long, impurities such as coupling difficulty and missing peptides begin to appear. The present invention uses the fourth fragment Boc-His(Trt)-Aib-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-OH to solve the problems of coupling difficulty and missing peptides.
[0019] (5) His 1 It is located at the first position of the N-terminus, and the nature of His itself is easy to racemize and difficult to couple. Therefore, when synthesizing the fourth fragment, Boc-His(Trt)-Aib dipeptide is used as the raw material for condensation, which can solve the problems of missing and racemization. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the HPLC spectrum of the second fragment of the present invention.
[0021] Figure 2 This is the HPLC spectrum of the third fragment of the present invention.
[0022] Figure 3 This is the HPLC spectrum of the fourth fragment of the present invention.
[0023] Figure 4 The HPLC spectrum of the crude semaglutide of the present invention.
[0024] Figure 5 The HPLC spectrum of the pure semaglutide of the present invention. DETAILED DESCRIPTION
[0025] The present embodiment provides a method for synthesizing semaglutide, comprising the following steps: solid phase synthesis of a first fragment of amino acids 21-31, a third fragment of amino acids 9-15, and a fourth fragment of amino acids 1-8, respectively; liquid phase synthesis of a second fragment with an amino acid at position 20 on the side chain; the first fragment, the second fragment, the third fragment, and the fourth fragment are sequentially coupled from the C-terminus to the N-terminus according to the semaglutide peptide sequence to obtain a semaglutide resin, and then cleavage and precipitation are performed to obtain a crude semaglutide.
[0026] The first fragment is: H-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0027] The second fragment is: Fmoc-Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-OH.
[0028] The third fragment is: Fmoc-Asp(OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu) 12 -Tyr(tBu) 13 -Leu 14 -Glu(OtBu) 15 -OH.
[0029] The fourth fragment is: Boc-His (Trt) 1 -Aib 2 -Glu(OtBu) 3 -Gly 4 -Thr(tBu) 5 -Phe 6 -Thr(tBu) 7 -Ser(tBu) 8 -OH.
[0030] The synthesis process of crude semaglutide is as follows: first, the first fragment and the second fragment are coupled to obtain a twelve-peptide resin of amino acids 20-31, and then the 19th, 18th, 17th and 16th amino acids are coupled step by step to obtain a sixteen-peptide resin of amino acids 16-31, and then the third fragment is coupled to obtain a twenty-tripeptide resin of amino acids 9-31, and then the fourth fragment is coupled to obtain a semaglutide resin, and finally the crude semaglutide is obtained by cleavage precipitation. The specific synthesis process is as follows: S1. Synthesis of 20-31 dodecapeptide resin Weigh the second fragment 10.504g (8.78mmol), HOBt 1.187g (8.78mmol), add 90ml DMF and stir to dissolve, add DIC 1.108g (8.78mmol) to activate for 15min, add H-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin, react with nitrogen, take the resin ninhydrin detection colorless and transparent, the coupling reaction is completed, add 90ml DMF to wash for 3min and then drain, repeat the washing three times; add 90ml 20% piperidine / DMF solution, react with nitrogen for 5min and then drain; then add 90ml 20% piperidine / DMF solution, react with nitrogen for 25min and then drain; add 90ml DMF to wash for 3min and then drain, repeat the washing six times to obtain H-Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0031] S2. Synthesis of 16-31 hexadecapeptide resin Weigh 4.100g (13.17mmol) of Fmoc-Ala-OH and 1.781g (13.17mmol) of HOBt, add 90ml of DMF to dissolve, add 1.662g of DIC (13.17mmol) with stirring, and activate with stirring for 10min. Add the activated amino acid solution to H-Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin, bubbling nitrogen reaction, taking resin ninhydrin detection colorless and transparent, the coupling reaction is completed, adding 90ml DMF to wash for 3min and then draining, and then repeating the washing three times to obtain Fmoc-Ala 19 -Lys 20 (Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0032] Add 80ml 20% piperidine / DMF solution, react with nitrogen for 5 minutes and then drain. Add 80ml 20% piperidine / DMF solution, react with nitrogen for 25 minutes and then drain. Add 80ml DMF to wash for 3 minutes and then drain. Repeat the washing six times. Then couple Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH in sequence, and finally remove the N-stage Fmoc to obtain H-Gly 16 -Gln(Trt) 17 -Ala 18 -Ala 19 -Lys20 (Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0033] S3, Synthesis of 9-31 twenty-tripeptide resin Weigh the third fragment 26.281g (20mmol), HOBt 1.187g (8.78mmol), add 90ml DMF and stir to dissolve, add DIC 1.108g (8.78mmol) to activate for 10-15min, add H-Gly 16 -Gln(Trt) 17 -Ala 18 -Ala 19 -Lys 20 (Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin, blow nitrogen to react, take the resin ninhydrin detection colorless and transparent, the coupling reaction is completed, add 90ml DMF to wash for 3min and then drain, repeat the washing three times, add 90ml 20% piperidine / DMF solution, blow nitrogen to react for 5min and then drain, add 90ml 20% piperidine / DMF solution, blow nitrogen to react for 25min and then drain; add 90ml DMF to wash for 3min and then drain, repeat the washing six times to obtain H-Asp(OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu) 12 -Tyr(tBu)13 -Leu 14 -Glu(OtBu) 15 -Gly 16 -Gln(Trt) 17 -Ala 18 -Ala 19 -Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0034] S4. Synthesis of 1-31 semaglutide resin Weigh the fourth fragment 28.577g (40mmol), HOBt 1.187g (8.78mmol), add 90ml DMF and stir to dissolve, add DIC 1.108g (8.78mmol) to activate for 10-15min, add H-Asp (OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu) 12 -Tyr(tBu) 13 -Leu 14 -Glu(OtBu) 15 -Gly 16 -Gln(Trt) 17 -Ala 18 -Ala 19 -Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-Lys 20 (Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf)28 -Gly 29 -Arg(pbf) 30 -Gly 31 -WangResin, bubbling nitrogen reaction, taking resin ninhydrin detection colorless and transparent, coupling reaction is completed, adding 90ml DMF to wash for 3min and then draining, repeating washing three times, adding 90ml DCM to wash for 3min, draining, repeating once. Add 90ml methanol to wash for 3min, draining, repeating once. Take out the resin and vacuum dry to obtain 26.240g semaglutide resin peptide Boc-His (Trt) 1 -Aib 2 -Glu(OtBu) 3 -Gly 4 -Thr(tBu) 5 -Phe 6 -Thr(tBu) 7 -Ser(tBu) 8 -Asp(OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu) 12 -Tyr(tBu) 13 -Leu 14 -Glu(OtBu) 15 -Gly 16 -Gln(Trt) 17 -Ala 18 -Ala 19 -Lys 20 (Ste(tBu)-γ-Glu(OtBu)-AEEA-AEEA)-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0035] S5. Cleavage and precipitation to obtain crude semaglutide Prepare the lysis solution, measure 234ml TFA, 13ml TIS, 6.5ml H2O, 6.5ml EDT, mix evenly, and ice bath to 6°C. Slowly add semaglutide resin peptide to the lysis solution, gradually return to room temperature and react for 2h. After the reaction is completed, filter, add 1560ml ice methyl tert-butyl ether to the filtrate for precipitation, centrifuge, add 260ml methyl tert-butyl ether to wash three times, centrifuge, discard the supernatant, and vacuum dry the precipitate to obtain 15.370g of off-white solid semaglutide crude product with a purity of 85.76% and a total yield of 85.11%.
[0036] S6. Purification of crude semaglutide The crude semaglutide was purified by high performance liquid preparative chromatography to obtain 7.796 g of semaglutide with a purity of 99.59% and a total product yield of 43.17%.
[0037] Specifically: the solid phase synthesis method of the first fragment is: S11, resin swelling: Weigh 9.84 g (6.0 mmol) of Wang Resin with a degree of substitution of 0.61 mmol / g, pour it into a solid phase reactor, add 100 ml of DCM, blow nitrogen, swell for 30 minutes, and drain the solvent.
[0038] S12, resin transformation: Weigh 3.568g (12mmol) of Fmoc-Gly-OH, 1.946g (14.4mmol) of HOBt, and 0.147g (1.2mmol) of DMAP, add 80ml of DMF, stir and dissolve, add 1.515g of DIC (12mmol) to activate for 10min, add the activated solution to the resin, blow nitrogen for reaction for 3h, then drain the reaction solution, add 80ml of DMF, wash for three minutes, then drain, repeat three times; add 40ml of DCM, 20ml of pyridine, and 20ml of acetic anhydride, blow nitrogen for reaction for 8h, then drain, add 80ml of DMF, wash for three minutes, then drain, repeat three times, add 80ml of DCM, wash for three minutes, then drain, add 80ml of anhydrous methanol, wash for three minutes, then drain, repeat once; put the resin in a vacuum drying oven and dry to constant weight. The degree of substitution was tested and measured to obtain 11.26 g (4.39 mmol) of Fmoc-Gly-Wang Resin with a degree of substitution of 0.39 mmol / g.
[0039] S13, removal of Fmoc protecting group: Add 80 ml of 20% piperidine / DMF solution, bubble nitrogen for reaction for 5 min, then drain; add 80 ml of 20% piperidine / DMF solution, bubble nitrogen for reaction for 25 min, then drain; add 80 ml of DMF, wash for 3 min, then drain, and repeat washing six times.
[0040] S14, coupled amino acids: Weigh 8.544g (13.17mmol) of Fmoc-Arg(pbf)-OH and 1.781g (13.17mmol) of HOBt, add 90ml of DMF to dissolve, add 1.662g of DIC (13.17mmol) with stirring, and activate with stirring for 10min. Add the activated amino acid solution to the resin, blow nitrogen to react, and take the resin for ninhydrin detection to find that it is colorless and transparent, and the coupling reaction is completed. Add 90ml of DMF to wash for 3min, then drain, and repeat the washing three times to obtain Fmoc-Arg(pbf)-Gly-Wang Resin.
[0041] S15, repeat the removal of Fmoc protecting group and coupling of amino acids: According to the amino acid sequence of the first fragment, Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH•H20, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH were coupled in sequence, and the N-terminal Fmoc protecting group was removed to obtain H-Glu(OtBu). 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
[0042] Specifically: the solid phase synthesis method of the third fragment is: S31, resin swelling: Weigh 2-CTC Resin with a substitution degree of 1.0 mmol / g and add it to the solid phase reaction column. Add 160 ml of DCM to swell for 30 minutes, and then remove the solution.
[0043] S32, resin transformation: Weigh 17.019 g (40 mmol) of Fmoc-Glu(OtBu)-OH, add 160 ml of DCM to dissolve, add 7.748 g (60 mmol) of DIEA, stir well and add to 2-CTC Resin, and react under nitrogen for 3 hours. After the reaction, drain the reaction liquid, add 136 ml of DCM, 16 ml of methanol, and 8 ml of DIEA, and react under nitrogen for 30 minutes. Drain the reaction liquid, add 160 ml of DMF, wash for 3 minutes, drain, and repeat washing three times to obtain Fmoc-Glu(OtBu)-CTCResin.
[0044] S33, removal of Fmoc protecting group: Add 160 ml of 20% piperidine / DMF solution, bubble nitrogen for reaction for 5 min, then drain; add 160 ml of 20% piperidine / DMF solution, bubble nitrogen for reaction for 25 min, then drain; add 160 ml of DMF, wash for 3 min, then drain, and repeat washing six times.
[0045] S34, coupled amino acids: Weigh 14.136g (40mmol) of Fmoc-Leu-OH and 5.406g (40mmol) of HOBt, add 160ml of DMF to dissolve, add 5.050g of DIC (40mmol) with stirring, and activate with stirring for 10min. Add the activated amino acid solution to the resin, blow nitrogen to react, and take the resin for ninhydrin detection to find that it is colorless and transparent, and the coupling reaction is completed. Add 160ml of DMF to wash for 3min, then drain, and repeat the washing three times to obtain Fmoc-Leu-Glu(OtBu)-Wang Resin.
[0046] S35, repeat the removal of Fmoc protecting group and coupling of amino acids: According to the sequence of the third fragment, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, and Fmoc-Asp(OtBu)-OH were coupled in sequence to obtain the third fragment fully protected resin. 160 ml of methanol was added to wash for 3 minutes, and the mixture was drained. The mixture was repeated once, and the resin was taken out and dried in vacuo.
[0047] S36, after drying, the resin was added to 500 ml of 20% TFE / DCM for full protection cleavage, reacted at room temperature for 2 h, filtered, and the filtrate was concentrated to obtain a white solid, which was then added to 200 ml of n-heptane for slurry washing three times, filtered, the filter cake was collected, and vacuum dried to obtain the third fragment Fmoc-Asp(OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu)12 -Tyr(tBu) 13 -Leu 14 -Glu(OtBu) 15 -OH.
[0048] Specifically: the solid phase synthesis method of the fourth fragment is: S41, resin swelling: Weigh 2-CTC Resin with a substitution degree of 1.0 mmol / g and add it to the solid phase reaction column. Add 160 ml of DCM to swell for 30 minutes, and then remove the solution.
[0049] S42, resin modification: Weigh 15.336 g (40 mmol) of Fmoc-Ser(tBu)-OH, add 160 ml of DCM to dissolve, add 7.748 g (60 mmol) of DIEA, stir well and add to 2-CTC Resin, react with nitrogen for 3 hours. After the reaction, drain the reaction solution, add 136 ml of DCM, 16 ml of methanol and 8 ml of DIEA, react with nitrogen for 30 minutes, drain the reaction solution, add 160 ml of DMF, wash for 3 minutes, drain, and repeat washing three times to obtain Fmoc-Ser(tBu)-CTCResin.
[0050] S43, removal of Fmoc protecting group: Add 160 ml of 20% piperidine / DMF solution, bubble nitrogen for reaction for 5 min, then drain; add 160 ml of 20% piperidine / DMF solution, bubble nitrogen for reaction for 25 min, then drain; add 160 ml of DMF, wash for 3 min, then drain, and repeat washing six times.
[0051] S44, coupled amino acids: Weigh 15.898g (40mmol) of Fmoc-Thr(tBu)-OH and 5.406g (40mmol) of HOBt, add 160ml of DMF to dissolve, add 5.050g of DIC (40mmol) with stirring, and activate with stirring for 10min. Add the activated amino acid solution to the resin, blow nitrogen to react, and take the resin for ninhydrin detection to find that it is colorless and transparent, and the coupling reaction is completed. Add 160ml of DMF to wash for 3min, then drain, and repeat the washing three times to obtain Fmoc-Leu-Glu(OtBu)-Wang Resin.
[0052] S45, repeat the removal of Fmoc protecting group and coupling of amino acid: According to the sequence of the third fragment, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, and Boc-His(Trt)-Aib-OH were coupled in sequence to obtain the fully protected resin of the fourth fragment. 160 ml of methanol was added to wash for 3 minutes, and the mixture was drained. The mixture was repeated once, and the resin was taken out and dried in vacuo.
[0053] S55, after drying, the resin was added to 500 ml 20% TFE / DCM for full protection cleavage, reacted at room temperature for 2 h, filtered, and the filtrate was concentrated to obtain a white solid, which was then added to 200 ml n-heptane for slurry washing three times, filtered, the filter cake was collected, and vacuum dried to obtain the fourth fragment Boc-His (Trt) 1 -Aib 2 -Glu(OtBu) 3 -Gly 4 -Thr(tBu) 5 -Phe 6 -Thr(tBu) 7 -Ser(tBu) 8 -OH.
[0054] Specifically: the liquid phase synthesis method of the second fragment is: S21. Weigh 5.559 g (15 mmol) of tBuO-Ste-OH and 2.071 g (18 mmol) of HOSu, add 55 ml of DCM, stir and dissolve, and slowly cool to 2°C in an ice bath. Weigh 3.714 g (18 mmol) of DCC, add 10 ml of DCM to dissolve, and dropwise add to the DCM solution of tBuO-Ste-OH and HOSu. After the addition is complete, slowly return to room temperature and stir to react. Monitor the reaction progress with HPLC. After the reaction is completed, filter, wash the filter cake with 20 ml DCM, combine the filtrate, add 55 ml saturated brine to wash twice, add 55 ml purified water to wash once, collect the organic phase, add 10.00 g anhydrous sodium sulfate to dry for 30 min, filter, concentrate the filtrate by rotary evaporation to a white solid, slowly add 55 ml 5% DCM / n-heptane solution (volume ratio), stir and beat at 10°C for 2 h, filter, wash the filter cake three times with a small amount of n-heptane, collect the filter cake, dry in vacuo, and collect the white solid to obtain tBuO-Ste-Osu.
[0055] S22, weigh 3.658g (18mmol) of H-Glu-OtBu, add 55ml DCM to dissolve, add 2.327g DIEA to adjust pH, slowly add tBuO-Ste-Osu, stir at room temperature to react, and monitor the reaction by HPLC. After the reaction is complete, add 55ml purified water, add 0.5mol / L dilute hydrochloric acid to adjust pH to 3-4, wash, collect the organic phase, and repeat washing twice. Collect the organic phase, add 10.00g anhydrous sodium sulfate, dry for 30min, filter, and obtain tBuO-Ste-Glu-OtBu.
[0056] S23, add tBuO-Ste-Glu-OtBu and HOSu 2.071g (18mmol) to 55ml DCM, stir and dissolve, ice bath 2℃. Weigh 3.714g (18mmol) of DCC, add 10ml DCM to dissolve, and drop into the DCM solution of tBuO-Ste-Glu-OtBu and HOSu. After the addition is completed, slowly return to room temperature and stir to react, and HPLC monitors the reaction. After the reaction is completed, filter, wash the filter cake with 20ml DCM, combine the filtrate, add 55ml saturated brine to wash twice, add 55ml purified water to wash once, collect the organic phase, add 10.00g anhydrous sodium sulfate to dry for 30min, filter, slowly add 55ml 5% DCM / n-heptane solution (volume ratio), stir and slurry at 10℃ for 2h, filter, wash the filter cake with a small amount of n-heptane three times, collect the filter cake, vacuum dry, and collect the white solid to obtain tBuO-Ste-Glu(OSu)-OtBu.
[0057] S24, add tBuO-Ste-Glu (OSu) -OtBu to 55ml THF and stir to dissolve, add 2.327g DIEA to adjust pH. Weigh 5.550g (18mmol) of H-AEEA-AEEA-OH, add 15ml purified water to dissolve, add dropwise to the THF solution of tBuO-Ste-Glu (OSu) -OtBu, and stir to react. HPLC monitors the reaction, after the reaction is completed, remove THF by rotary evaporation, add 110ml EA to dissolve, add 55ml saturated salt water, adjust pH to 3-4, wash and collect the organic phase, repeat washing twice, add 55ml purified water to wash once. Collect the organic phase, add 10.00g anhydrous sodium sulfate and dry for 30min. Filter, add 27.5 ml EA to dissolve, add the solution to 275 ml ice n-heptane, crystallize in an ice bath at -10°C for 2 hours, centrifuge to remove the supernatant, add 55 ml n-heptane to wash the product, centrifuge, discard the supernatant, repeat the washing twice, collect the oily product, and dry in vacuo to obtain tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu.
[0058] S25, add tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu and HOSu 2.071g (18mmol) into 55ml DCM and stir to dissolve, ice bath at 2℃. Weigh 3.714g (18mmol) of DCC, add 10ml DCM to dissolve, and add dropwise into the DCM solution of tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu and HOSu. After the addition is completed, slowly return to room temperature and stir to react, and monitor the reaction by HPLC. After the reaction is completed, filter, wash the filter cake with 20 ml CM, combine the filtrate, add 55 ml saturated brine to wash twice, add 55 ml purified water to wash once, collect the organic phase, add 10.00 g anhydrous sodium sulfate to dry for 30 min, filter, slowly add 55 ml 3% DCM / n-heptane solution (volume ratio), stir and beat at 10°C for 2 h, filter, wash the filter cake three times with a small amount of n-heptane, collect the filter cake, dry in vacuo, and collect the white solid to obtain tBuO-Ste-Glu(AEEA-AEEA-Osu)-OtBu.
[0059] S26. Dissolve tBuO-Ste-Glu(AEEA-AEEA-Osu)-OtBu in 55 ml DCM, add 4.654 g DIEA (36 mmol) to adjust the pH, and stir to dissolve. After complete dissolution, add 7.288 g Fmoc-Lys-OH•HCl, stir the reaction at room temperature, and monitor the reaction by HPLC. After the reaction is completed, add 55 ml saturated saline, adjust the pH to 3-4, wash and collect the organic phase, repeat the washing twice, and add 55 ml purified water to wash once. Collect the organic phase, add 10.00 g anhydrous sodium sulfate and dry for 30 minutes. Filter, add 55 ml DCM to dissolve, purify by column chromatography on 200-300 mesh silica gel, and elute with MeOH / DCM to obtain an oily product Fmoc-Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-OH.
[0060] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for illustrating the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which shall fall within the scope of the present invention to be protected. The scope of protection of the present invention shall be defined by the attached claims and their equivalents.
Claims
1. A method for synthesizing semaglutide, characterized in that: The method comprises the following steps: respectively solid-phase synthesizing a first fragment of amino acids at positions 21 to 31, a third fragment of amino acids at positions 9 to 15, and a fourth fragment of amino acids at positions 1 to 8; liquid-phase synthesizing a second fragment with amino acids at positions 20 on the side chain; sequentially coupling the first fragment, the second fragment, the third fragment, and the fourth fragment from the C-terminus to the N-terminus according to the peptide sequence of semaglutide to obtain semaglutide resin, and then cleaving and precipitating to obtain a crude semaglutide product.
2. The method for synthesizing semaglutide according to claim 1, characterized in that: The solid phase synthesis method of the first fragment is: using Wang Resin as a solid phase carrier, sequentially coupling Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH•H20, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, removing the N-terminal Fmoc protecting group, and obtaining H-Glu(OtBu) 21 -Phe 22 -Ile 23 -Ala 24 -Trp(Boc) 25 -Leu 26 -Val 27 -Arg(pbf) 28 -Gly 29 -Arg(pbf) 30 -Gly 31 -Wang Resin.
3. The method for synthesizing semaglutide according to claim 2, characterized in that: The Wang Resin substitution degree ranges from 0.2 mmol / g to 1.0 mmol / g.
4. The method for synthesizing semaglutide according to claim 1, characterized in that: The solid phase synthesis method of the third fragment is: using 2-CTC Resin as a solid phase carrier, using Fmoc-Glu (OtBu) -OH to transform the resin, and then sequentially coupling Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Val-OH, Fmoc-Asp (OtBu) -OH to obtain a fully protected resin for the third fragment, and using a cleavage solution to perform fully protected cleavage to obtain the third fragment Fmoc-Asp (OtBu) 9 -Val 10 -Ser(tBu) 11 -Ser(tBu) 12 -Tyr(tBu) 13 -Leu 14 -Glu(OtBu) 15 -OH.
5. The method for synthesizing semaglutide according to claim 1, characterized in that: The solid phase synthesis method of the fourth fragment is: using 2-CTC Resin as a solid phase carrier, using Fmoc-Ser(tBu)-OH to transform the resin, and then sequentially coupling Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Boc-His(Trt)-Aib-OH to obtain a fully protected resin for the fourth fragment, and using a cleavage solution to perform fully protected cleavage to obtain the fourth fragment Boc-His(Trt) 1 -Aib 2 -Glu(OtBu) 3 -Gly 4 -Thr(tBu) 5 -Phe 6 -Thr(tBu) 7 -Ser(tBu) 8 -OH.
6. The method for synthesizing semaglutide according to claim 1, characterized in that: The liquid phase synthesis method of the second fragment is: using tBu-Oct-OH as the starting material, condensing H-Glu-OtBu, H-AEEA-AEEA-OH, and Fmoc-Lys-OH•HCl in sequence from the N-terminus to the C-terminus to obtain Fmoc-Lys 20 (Ste(OtBu)-γ-Glu(OtBu)-AEEA-AEEA)-OH.
7. The method for synthesizing semaglutide according to claim 1, characterized in that: The volume ratio of the cleavage reagent used in the cleavage step of the semaglutide resin is TFA:TIS:EDT:H2O=85-95:2-5:0-2:2-5, the cleavage time is 1.5h-3.0h, and the cleavage temperature is 20°C-30°C.
8. The method for synthesizing semaglutide according to claim 1, characterized in that: The precipitation reagent used in the precipitation step of the semaglutide resin is ethyl ether, isopropyl ether or methyl tert-butyl ether.
9. The method for synthesizing semaglutide according to claim 1, characterized in that: The coupling reagents used for coupling between amino acids within a fragment and between adjacent fragments are A+B, A+B+D or C+D, where A is HOAt, HOBt, 6-Cl-HOBt, HONB, ethyl 2-oximecyanoacetate, B is DIC, DCC, EDC•HCl, C is HATU, HBTU, TBTU, TSTU, PyBOP, PyAOP, and D is DIEA, DMAP, NMM.
10. The method for synthesizing semaglutide according to claim 1, characterized in that: The deprotection solution for removing the Fmoc protecting group in the first segment, the third segment and the fourth segment is a 10% to 20% piperidine / DMF mixed solution or a 3% to 10% DBU / DMF mixed solution.
Citation Information
Patent Citations
Acylated GLP-1 compounds
CN101133082A
Solid-phase synthesis method of Sermaglutide
CN106478806A
Synthesis method of semaglutide
CN110372785A
Synthesis method of semaglutide
CN112028986A
Cited By
Mixture of semeglutide intermediates and preparation method of semeglutide
CN120554481A
A mixture of semaglutide peptide intermediates and a method of preparing semaglutide
CN120554481B
